Details of the Drug Combination

General Information of Drug Combination (ID: DC6QED9)

Drug Combination Name

Mesalazine Minocycline

Indication

Disease Entry	Status	REF
Inflammatory Bowel Diseases	Phase 2	[1]

Component Drugs

Mesalazine DMOL5IU

Minocycline DMVN5OH

Small molecular drug

2D MOL

3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Mesalazine

Disease Entry	ICD 11	Status	REF
Diverticulitis	N.A.	Approved	[2]
Proctitis	DB33.Z	Approved	[3]
Ulcerative colitis	DD71	Approved	[4]
Ulcerative proctosigmoiditis	N.A.	Approved	[5]

Mesalazine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Prostaglandin G/H synthase 1 (COX-1)	TT8NGED	PGH1_HUMAN	Inhibitor	[9]
------------------------------------------------------------------------------------

Mesalazine Interacts with 4 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[10]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[11]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[11]
Organic anion transporting polypeptide 2B1 (SLCO2B1)	DTPFTEQ	SO2B1_HUMAN	Substrate	[11]
------------------------------------------------------------------------------------

Mesalazine Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
RNA cytidine acetyltransferase (hALP)	DEZV4AP	NAT10_HUMAN	Metabolism	[12]
------------------------------------------------------------------------------------

Indication(s) of Minocycline

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Approved	[6]
Actinomycosis	N.A.	Approved	[6]
Acute gonococcal cervicitis	N.A.	Approved	[6]
Bacterial infection	1A00-1C4Z	Approved	[7]
Bartonellosis	N.A.	Approved	[6]
Bronchitis	CA20	Approved	[6]
Brucellosis	N.A.	Approved	[6]
Chancroid	N.A.	Approved	[6]
Listeriosis	N.A.	Approved	[6]
Lymphogranuloma venereum	N.A.	Approved	[6]
Ornithosis	N.A.	Approved	[6]
Periodontitis	DA0C	Approved	[6]
Pneumonia	CA40	Approved	[6]
Q fever	N.A.	Approved	[6]
Relapsing fever	N.A.	Approved	[6]
Rickettsialpox	N.A.	Approved	[6]
Rocky mountain spotted fever	N.A.	Approved	[6]
Syphilis	N.A.	Approved	[6]
Trachoma	N.A.	Approved	[6]
Tularemia	1B94	Approved	[6]
Typhus	N.A.	Approved	[6]
Urinary tract infection	GC08	Approved	[6]
Yaws	N.A.	Approved	[6]
Rosacea	ED90.0	Phase 2	[8]
Plague	N.A.	Investigative	[6]
Sinusitis	CA0A.Z	Investigative	[6]
Vibrio cholerae infection	1A00	Investigative	[6]

Minocycline Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)	TTQ8KVI	F4NA87_STAAU	Binder	[13]
------------------------------------------------------------------------------------

Minocycline Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 2E1 (CYP2E1)	OTHQ17JG	CP2E1_HUMAN	Increases ADR	[14]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT06201793) Minocyclin in Ulcerative Colitis as Added on Therapy
2	Colonic diverticular disease. Nat Rev Dis Primers. 2020 Mar 26;6(1):20.
3	Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository. Digestion. 2018;97(1):59-63.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4655).
5	Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. J Crohns Colitis. 2021 Jul 5;15(7):1184-1196.
6	Minocycline FDA Label
7	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
10	Transport studies with 5-aminosalicylate. Eur J Clin Pharmacol. 2006 Oct;62(10):871-5.
11	Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos. 2011 Jun;39(6):1097-102.
12	NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis. Z Gastroenterol. 2008 Mar;46(3):259-65.
13	Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66.
14	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.